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Infection with theﬁlarialnematodeWuchereria bancrofti canleadto lymphedema, hydrocele, andelephantiasis.Since adult worms
cause pathology in lymphatic ﬁlariasis (LF), it is imperative to discover macroﬁlaricidal drugs for the treatment of the infection.
Endosymbiotic Wolbachia in ﬁlariae have emerged as a new target for antibiotics which can lead to macroﬁlaricidal eﬀects. In
Ghana, a pilot study was carried out with 39 LF-infected men; 12 were treated with 200mg doxycycline/day for 4 weeks, 16
were treated with a combination of 200mg doxycycline/day + 10mg/kg/day rifampicin for 2 weeks, and 11 patients received
placebo. Patients were monitored for Wolbachia and microﬁlaria loads, antigenaemia, and ﬁlarial dance sign (FDS). Both 4-week
doxycycline and the 2-week combination treatment reduced Wolbachia load signiﬁcantly. At 18 months posttreatment, four-week
doxycycline resulted in 100% adult worm loss, and the 2-week combination treatment resulted in a 50% adult worm loss. In
conclusion, this pilot study with a combination of 2-week doxycycline and rifampicin demonstrates moderate macroﬁlaricidal
activity against W. bancrofti.
1.Introduction
Approximately 120 million people in Africa, Asia, and
America are infected with the ﬁlarial nematodes Wuchereria
bancrofti or Brugia malayi, resulting in lymphatic ﬁlariasis
(LF), of which more than 40 million suﬀer from the
debilitating lymphatic pathologies such as lymphedema,
elephantiasis, and hydrocele. LF is one of the most common
causes of global disability [1]. The classical drugs diethylcar-
bamazine (DEC), ivermectin (IVM), and albendazole (ALB)
have been used for the last two decades as the major mode
of intervention for ﬁlarial infection in successful mass drug
administration (MDA) programmes [2–4]. However, these
drugs are mainly microﬁlaricidal [5–10], that is, killing
the ﬁrst larval stage, the microﬁlariae (Mf). The currently
availableregimes have beenoptimised to obtain a decreasein
transmission by reducing the Mf load in a given population
at both low cost and logistical eﬀort.
Because ivermectin does not, and DEC plus albendazole
only partially kill adult worms that are the causes of pathol-
ogy in LF (urogenital disorders and lymphedema), research
is ongoing to discover novel antiﬁlarial drugs with strong
macroﬁlaricidal activity. A macroﬁlaricidal drug would help
to prevent excruciating sequela and ensure elimination of
the disease as a public health problem. One promising
area is the use of antibiotics to deplete the Wolbachia
endosymbionts found in most ﬁlarial species, which leads
to the inhibition of worm development, embryogenesis,2 Journal of Parasitology Research
fertility, and viability in human onchocerciasis [11–14]a n d
LF [15–18]. We have recently demonstrated that a four-
week course of doxycycline, followed by a single dose of
ivermectin treatment in bancroftian ﬁlariasis, is eﬀective at
reducing Wolbachia levels by 95% and, more importantly, it
leads to strong macroﬁlaricidal activity with improvement
of pathology [16, 17]. However, a shorter regimen with
antibiotics or more eﬀective antiﬁlarial drugs would be
advantageous for the treatment of the large populations or
for individual treatment, for example, in outpatient clinics,
and for children.
A three-week course of doxycycline followed by a single
dose of ivermectin/albendazole treatment had been shown
by us to reduce Wolbachia single gene copies per microﬁlaria
(Mf) by 86%, which abolished microﬁlaraemia for more
than one year and ameliorated adverse reactions to standard
antiﬁlarial drugs used for mass chemotherapy [19]. How-
ever, this treatment did not show macroﬁlaricidal activity.
Nevertheless, three-week doxycycline in combination with
a single dose of DEC did show a macroﬁlaricidal eﬀect
[20], demonstrating that diﬀerent combinations with doxy-
cycline could lead to a shorter regimen with macroﬁlaricidal
eﬀect.
Studies carried out by diﬀerent research groups, both
in vitro and in vivo in animal models, indicate that, besides
doxycycline, other antibiotics registered for human use,
especially rifampicin, also reduced Wolbachia from adult
worms and damaged developing embryos and, at a higher
concentration,killedadultworms[21–23].Infact,inmurine
ﬁlariasis using Litomosoides sigmodontis, administration of
rifampicin in combination with doxycycline could reduce
the treatment time by approximately 50% [23,S p e c h ta n d
Hoerauf, unpublished]. This implies that a combination of
rifampicin and doxycyclinemight be complementary to each
other leading to a macroﬁlaricidal activity with a shorter
eﬀective regimen and a better Wolbachia depletion capacity.
Rifampicin has also been tried in human onchocerciasis and
2–4 weeks of 10mg/kg/d showed antiwolbachial activity and
reduction of worm fertility [24]. Based on these promising
results from animal and human trials, and given that
rifampicin is a registered drug that can be taken by children,
clinical trials were initiated to investigate its antiﬁlarial
properties against LF in humans.
Thus, the intention of this trial was to test if the
combination of doxycycline and rifampicin would be more
eﬀective against bancroftian ﬁlariasis in humans compared
to doxycycline alone. In this study, we report on a trial
with doxycycline (200mg/day) alone for 4 weeks versus
a combination of rifampicin (10mg/kg body weight/day)
plus doxycycline (200mg/day) for two weeks versus placebo
matching doxycycline.
2.Materialsand Methods
This randomized open trial was conducted in the coastal
villages of Asanta, Sanwoma, Agyambra, and Miamia in the
N z e m aE a s ta n dt h eA h a n t aW e s tD i s t r i c ti nt h eW e s t e r n
Region of Ghana from 2005 to 2008. The study site was
selected based on an established occurrence of W. bancrofti
infection within the surrounding region and clinical obser-
vations consistent with symptomatic disease in the villagers
[16, 25, 26]. Written informed consent was obtained from all
participants, and the study was approved by the Committee
on Human Research, Publication and Ethics of the Kwame
Nkrumah University of Science and Technology and Komfo
Anokye Teaching Hospital, Kumasi, Ghana. The study
conformed to the principles of the Helsinki Declaration of
1964 (as revised in 1983, 2000, and 2004).
Individualseligibleforparticipationwereadultmenaged
18–60 years, with a minimum body weight of 40kg, in
good health without any clinical condition requiring chronic
medication. Exclusion criteria encompassed a microﬁlarial
load <20Mf/mL, abnormal hepatic and renal enzymes
(above AST [0–40IU/L], ALT [0–45IU/L], creatinine [53–
126μmol/L]) assessed by dipstick chemistry, and alcohol or
drug abuse. Leukocyte and diﬀerential counts of thin blood
smears were also done.
2.1. Doxycycline and Rifampicin Treatment. In all, 48 men
were recruited for the study, and 39 completed the treatment
course (Figure 1). Nine men dropped out and could not
complete the treatment because they either moved from the
villages or could not comply with the daily observed treat-
ment because of ﬁshing activities. Of the 39 men, 12 were
treated with 200mg doxycycline/d for 4 weeks, 16 patients
with 200mg doxycycline/d + 10mg/kg/d rifampicin for
2 weeks + 2 weeks placebo matching doxycycline, and 11
patients were treated with placebo matching doxycycline for
4 weeks. Due to unavailability of rifampicin placebo at the
time, the rifampicin plus doxycycline treatment arm was
an open study while for the doxycycline capsules matching
placebo were available so this part of the trial was placebo
controlled.
Treatment was administered and monitored by a trial
clinician on a daily basis. Four months after the start of
treatment, all participants received a standard oral dose
of 400mg albendazole (GlaxoSmithkline) and 150μg/kg
ivermectin (Mectizan, Merck, Sharp & Dohme) in 2006 and
received another dose at the end of the treatment in 2008.
2.2. OutcomeMeasurement. The primary outcome measure-
ment of this study was assessment of adult worm vitality
using ultrasonography (USG) [26].
2.3. Ultrasound (USG) Examinations. Study participants
were examined before treatment and at 12, 18, and 24
months using a portable ultrasound machine (SONOSITE
180 Plus) equipped with a 7.5MHZ linear transducer as
previously described [26, 27]. Patients were screened for
living adult ﬁlarial worms detectable in lymphatic vessels of
the scrotum and the spermatic cord. Ultrasound ﬁndings
were documented by printouts and digital video recordings
of each worm nest in the b-, m- and Pulse Wave Doppler-
modes. The locations of the worm nest(s) (e.g., left or right
supra-,para-andinfratesticular area,lymphaticvesselsofthe
spermatic cord) were documented for longitudinal analysis
of appearance, stability, or disappearance, respectively.Journal of Parasitology Research 3
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Figure 1: Recruitment and treatment proﬁle of the pilot study.
2.4. Determination of Microﬁlarial (Mf) Load. For a quick
screening at night to identify people who had Mf, the
W. bancrofti Mf load was determined by microscopic
examination of ﬁnger prick blood samples [25]i nt h e
communities. Subsequently, eligible patients donated 10ml
of venous blood for accurate quantiﬁcation using Whatman
Nucleopore ﬁlter method as described previously [25]. The
same volume of blood was taken from patients present at 4,
12,18,and24monthsafterthecommencementoftreatment.
At each time point, plasma was taken from the remaining
sample, aliquoted, and frozen at −80◦C for later analysis of
antigenaemia.4 Journal of Parasitology Research
2.5. Determination of Wolbachia Levels in Mf by PCR.
Wolbachia content was quantiﬁed by real-time PCR of
the W. bancrofti Wolbachia–ftsZ gene (AF081198 NCBI)
derivedfrom500–1000microﬁlariaeusingaRotorGene3000
(Corbett Research, Inc., Sydney, Australia) at pretreatment
and 4 months after treatment onset. Details of the technique
aregivenelsewhere [16,25].Brieﬂy,DNAwasextracted from
500–1000MftrappedonaWhatmanﬁlterusingtheQIAamp
kit (Qiagen, Hilden, Germany) following the kit protocol
with the exception that the 56◦C incubation was performed
overnight. As previously described [16, 25], primers ampli-
ﬁed a 256bp fragment of the Wolbachia-ftsZ gene, and a
TaqMan probe (Invitrogen, Darmstadt, Germany) for the
same sequence was used to detect the product by real-time
PCR. The PCR products were quantiﬁed by comparing with
astandard curveoftheplasmid containingtheftsZ fragment.
2.6. Determination of Circulating Filarial Antigenaemia.
Adult W. bancrofti antigen was measured with the TropBio
ELISA test kit (TropBio, Townsville, Australia). The kit
protocolwasfollowed withthefollowing exceptions:samples
were boiled in sample diluent and diluted (1:20 ratio) with
the diluent [14, 15]; 50μL of the diluted plasma was added
to plate wells; the plates were incubated overnight. Samples
were tested in duplicate. The optical density at 414nm was
recorded from plasma samples taken before treatment and
from the 12-, 18-, and 24-month followup time points.
Antigen units were determined using a standard curve from
standards provided by the manufacturer and the ﬁnal units
multiplied by the dilution factor of 20.
2.7. Data Analysis. Depletion of Wolbachia from Mf, the
number of microﬁlaria and ﬁlarial dance sign (FDS) and the
levels of circulating ﬁlarial antigen (CFA) were summarized
as medians and 25th and 75th percentiles for the diﬀerent
treatment groups. Changes in medians at baseline and
subsequent followups were analyzed using Wilcoxon Signed
Rank test. The Kruskal-Wallis test and the Mann-Whitney-
U test were used for comparisons between the treatment
groups.
Mf-positive individuals as well as individuals showing
ﬁlarial dance sign (FDS) before and after treatment were
given as number of positive individuals per total number
of persons examined and as percentages. The diﬀerences
between the treatment groups were evaluated using Fisher’s
exact test. Two-tailed P values lower than .05 were consid-
ered signiﬁcant.
All analyses were done using Predictive Analysis Software
(PASW) version 18.
3.Results
Forty-eight men were randomized for the study, and 39
completed the treatment (Figure 1). Of the 39 men, 12 were
treated with 200mg doxycycline/day for 4 weeks, 16 were
treated with a combination of 200mg doxycycline/day +
10mg/kg/day rifampicin for 2 weeks, and 11 patients
receivedplacebomatchingdoxycycline.Ninepatientsdidnot
complete the allocated intervention, three from the doxy-
cycline 4-week arm, one from the doxycycline + rifampicin
combination, and ﬁve from the placebo group. There was no
statistical diﬀerence among the three groups regarding the
age distribution (P = .287, Kruskal-Wallis test).
3.1. Adverse Events Experienced by Patients during Treat-
ment. All drugs were well tolerated. In all, eight out of
the 48 patients randomized for the treatment experienced
slight adverse eﬀects. Three patients were from the placebo
group, another three from the 200mg doxycycline/d +
10mg/kg/d rifampicin group, and two were from the 4-week
doxycycline group. Of the three placebo-treated patients,
one had diarrhea for one day, and the two had dizziness
for one day and three days, respectively. Of the three
rifampicin- and doxycycline-treated group, one had nausea
after eating for one day and two experienced dizziness for
a day each; from the 4-week doxycycline group, one had
stomachache for a dayand anotherhad headache with cough
for 3 days. Oral rehydration salt was administered to the
patientswithgastrointestinal complaints.Apartfromthis,no
interventionswereneeded.Therewasnostatisticaldiﬀerence
in the number of patients who experienced adverse events
between the three groups (P = .847).
3.2. Primary Outcome Analysis
3.2.1. Measurement of Adult Worm Vitality. Since ultra-
sonography is noninvasive and has been proven to be
eﬀective for assessing a macroﬁlaricidal eﬀect [16, 17, 27–
29], this method was used as the primary tool for this study,
while circulating ﬁlarial antigen (CFA) levels in plasma were
assessed as a conﬁrmative parameter. At 12 months, the
4-week doxycycline group had 80% worm loss while the
combination treatment of 2-week doxycycline + rifampicin
had 38% worm loss and the placebo group had no change
in worm vitality (Table 1). The same trend could be seen in
t h en u m b e ro fF D S .W h i l et h e r ew a sad e c r e a s eo fF D Si n
the doxycycline and the combination group (P = .006 and
P = .034, resp.; Wilcoxon signed rank test), there was rather
an increase in the placebo group (P = .083, Table 1). At 18
months after treatment, this pattern remained the same with
the 4-week doxycycline group having 100% loss of worm
nests, the 2-week doxycycline + rifampicin group showing
a 50% loss of worm nests while placebo group remained
unchanged (Table 1). This trend was also observed at 24
months but less signiﬁcantly (Table 1), which is most likely
due to possible reinfection ofthe patients, asobserved earlier
[16].Therewas notsigniﬁcant reductionintheantigenaemia
compared to the loss of worms by USG as shown in our
previous studies [14–18]. This was probably due to very few
people donating blood during the followup time points for
the antigenaemia analyses.
3.3. Secondary Outcomes. Table 1 also illustrates the changes
in microﬁlaraemia and Wolbachia/Mf from baseline and at
followup time points. Baseline measurements were similar
between the allocated treatment groups, except the Mf
load which was higher in the placebo group than the twoJournal of Parasitology Research 5
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treatment groups (P = .001, Kruskal-Wallis test). However,
the Mf loads between the 4-week doxycycline group and
the 2-week doxycycline+ rifampicin group were comparable
(P = .378, Mann-Whitney-U test) (Table 1). At 12 months
after treatment, the 4-week doxycycline regimen completely
reduced the Mf load (P = .012). Signiﬁcant reductions in
microﬁlaraemia were also seen in the 2-week doxycycline +
rifampicin (P = .003) and the placebo (P = .043) regimens
(Table 1). However, at 18 and 24 months, while the 4-week
doxycycline and 2-week doxycycline + rifampicin regimens
continued to maintain signiﬁcantly low microﬁlarial loads,
there was a rise in Mf loads in the placebo patients (Table 1).
The Wolbachia loads in the Mf (ftsZ copies/Mf) at four
months posttreatment were reduced by 93% (P = .002,
Wilcoxon signed rank test) in the 4-week doxycycline group,
and85% (P = .034,Wilcoxonsignedrank test)inthe2-week
doxycycline + rifampicin group, but there was no change in
the placebo group (P = .138, Wilcoxon signed rank test,
Table 1).
4.Discussion
Lymphatic ﬁlariasis (LF) is a common cause of disability in
humans.OfthepresentlyusedantiﬁlarialdrugstocombatLF
within the scope of MDA only DEC—which is not used in
African countries coendemic for onchocerciasis—has mod-
erate macroﬁlaricidal activity [30–33]. Doxycycline is a safe
and eﬃcacious drug for treatment of LF infection. Previous
trials indicate that an eight-, a six- or a four-week course
of 200mg/day followed by a single dose of ivermectin or a
three-week course of 200mg/day followed by a single dose
of DEC leads to gradual and sustained loss of Mf from host
blood and has strong macroﬁlaricidal activity [15–18, 34,
35]. The advantage of a macroﬁlaricidal drug is that it targets
theadultwormsthatare theinducersoflymphaticpathology
and thus can bring direct relief to individual patients that
seek treatment, for example, in outpatient clinics, without
having torely on theindirect meansofreduction ofinfection
pressure due to transmission control by microﬁlaricidal
drugs [36]. However, the previously published doxycycline
regimens are long, and a shorter regimen is desirable to
complement classical antiﬁlarial drugs [36].
The present trial conﬁrmed a previous report that 4-
week doxycycline results in more than 80% macroﬁlaricidal
eﬀect [17]. The second and novel result of this study is that
the combination of rifampicin with doxycycline had an anti-
wolbachial eﬀect on W. bancrofti in humans and this eﬀect
occurred with a shorter (2 weeks) course of treatment. Here
we describe the maintenance of very low microﬁlaraemia at
12 and 18 months after doxycycline + rifampicin treatment
and a moderate (50%) macroﬁlaricidal activity indicated
by the loss of worm nests in the combination group. In
contrast, in the placebo patients the worm nests remained
stable throughout the followup examinations.
Asdiscussed above,ourthree-week course ofdoxycycline
alone was shown to abolish microﬁlaraemia for more
than one year [19]; however, this treatment did not show
macroﬁlaricidal activity. Nevertheless, the same three-week
doxycycline regimen with DEC did show a macroﬁlaricidal
eﬀect [20], demonstrating that the DEC might have some
added eﬀect on doxycycline. Our current results show that a
treatment with a combination of doxycycline and rifampicin
for two weeks also has a macroﬁlaricidal eﬀect. Thus, this
pilot study has provided indirect evidence that rifampicin
might have a synergetic eﬀect with doxycycline. A current
ﬁeld try aims to conﬁrm the synergetic eﬀects of these two
drugs.
It is likely that 2-week doxycycline + rifampicin could
havestrongermacroﬁlaricidalactivitythanthe50%observed
when patients are observed after a longer period. However,
due to the high transmission rate in this area, longer
followups are not useful because of reinfection. Notwith-
standing, the present study showing 2-week doxycycline +
rifampicin having a partial macroﬁlaricidal eﬀect is encour-
aging in the sense that it serves as further proof that anti-
wolbachial therapy as a treatment against LF may be possible
with a shorter regimen if antiwolbachial drugs are combined.
The results of the combination of 3-week doxycycline
and rifampicin in an ongoing trial will provide more infor-
mation.
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